Egrifta is typically self-administered by the patient at home after receiving training from a healthcare provider. It is important to follow these general instructions:

1. Prepare the Injection:
   
   
   • Wash your hands thoroughly with soap and water.
     
     
   • Prepare the Egrifta syringe or vial as directed by your healthcare provider. The medication comes in a prefilled syringe, which makes it easier for home use.
     
     
2. Choose an Injection Site:
   
   
   • The recommended injection site is the lower abdomen, at least 2 inches away from the belly button. You can rotate the injection sites to avoid irritation.
     
     
3. Inject the Medication:
   
   
   • Insert the needle into the skin at a 90-degree angle.
     
     
   • Slowly push the plunger to inject the medication. After the injection, remove the needle and dispose of it properly in a puncture-resistant container.
     
     
4. Post-Injection Care:
   
   
   • Apply light pressure to the injection site with a cotton ball or gauze if necessary.
     
     
   • Rotate the injection sites regularly to minimize discomfort or irritation.
     
     
5. Follow Up with Healthcare Provider:
   
   

Regular follow-ups with your healthcare provider are essential to monitor progress and adjust the dosage if needed.

Egrifta (tesamorelin) works by mimicking the action of growth hormone-releasing hormone (GHRH). GHRH is a natural hormone in the body that stimulates the pituitary gland to release growth hormone (GH).

Growth hormone has several effects on the body, including:

• Reduction of visceral fat: Tesamorelin stimulates the release of growth hormone, which, in turn, helps to reduce excess abdominal fat. This is particularly important for individuals with HIV-associated lipodystrophy, where abnormal fat accumulation in the abdominal area is a common issue.
  
  
• Increase in fat metabolism: Growth hormone promotes lipolysis, the breakdown of fat cells, which can help to redistribute fat away from the abdomen and improve overall fat composition.
  
  
• Improvement in body composition: Tesamorelin has been shown to not only reduce abdominal fat but also help to increase lean body mass, such as muscle mass, in patients with HIV-related lipodystrophy.
  
  

By reducing the amount of abdominal fat, Egrifta may help improve both the appearance and overall health of individuals living with HIV who are experiencing lipodystrophy.

Like all medications, Egrifta can cause side effects. Some of the common side effects include:

Common Side Effects:

• Injection site reactions: Pain, redness, or swelling at the site of injection.
  
  
• Headache: Some individuals may experience mild headaches during treatment.
  
  
• Joint pain: Musculoskeletal discomfort, including pain in the joints or muscles, may occur.
  
  
• Nausea: Some individuals may feel mildly nauseous or experience mild gastrointestinal discomfort.
  
  

Serious Side Effects:

• Increased blood sugar: Egrifta may increase blood sugar levels, particularly in patients with pre-existing diabetes or insulin resistance. This can result in hyperglycemia, requiring careful monitoring of blood sugar levels.
  
  
• Carpal tunnel syndrome: There have been reports of carpal tunnel syndrome, which causes pain, numbness, or weakness in the hands and wrists.
  
  
• Edema: Some patients may develop fluid retention, which can lead to swelling in the feet, ankles, or hands.
  
  
• Allergic reactions: Though rare, some individuals may experience allergic reactions to Egrifta, including symptoms like rash, itching, or difficulty breathing.
  
  

If you experience any serious side effects, contact your healthcare provider immediately.

• Diabetes and Blood Sugar: Egrifta can affect insulin sensitivity and glucose metabolism, so it is essential for individuals with diabetes or those at risk of diabetes to be monitored regularly during treatment.
  
  
• Pregnancy and Breastfeeding: Egrifta is not recommended for use during pregnancy or breastfeeding, as its safety in these populations has not been established.
  
  
• Pre-existing Conditions: Patients with liver disease, kidney problems, or a history of joint pain should consult their healthcare provider before starting Egrifta.
  
  

Injection Site Reactions: It is important to rotate injection sites to minimize irritation or discomfort. If any swelling, redness, or pain persists, consult your doctor.

Egrifta can interact with other medications or conditions, including:

• Growth hormone therapy: Since Egrifta stimulates the production of growth hormone, it may interfere with or exacerbate the effects of other growth hormone treatments.
  
  
• Medications affecting insulin: Egrifta may impact insulin sensitivity or glucose metabolism, so individuals with diabetes or those using insulin should be closely monitored for changes in their blood sugar levels.
  
  
• Other peptide or hormone therapies: Be cautious when using Egrifta in combination with other peptide-based or hormone therapies, as it could influence their effectiveness or safety.
  
  

Always inform your healthcare provider about any other medications or supplements you are taking to avoid potential interactions.

The recommended dose of Egrifta is typically 2 mg administered once daily via subcutaneous injection. The treatment duration and dosage may vary depending on the individual’s response and the healthcare provider’s recommendations.

Egrifta is a prescription-only medication, meaning it must be prescribed by a licensed healthcare provider. Your doctor will evaluate your specific medical condition, including the presence of HIV-associated lipodystrophy, and determine whether Egrifta is suitable for you. Regular follow-up visits are essential for monitoring the effectiveness of the medication and any potential side effects.

• What is Egrifta?
  Egrifta is a prescription medication used to reduce excess abdominal fat in adults with HIV-related lipodystrophy.

• How does Egrifta work?
  It is a growth hormone–releasing factor (GRF) analog that stimulates the pituitary gland to release growth hormone, which helps reduce visceral fat.

• Who is Egrifta prescribed for?
  It is specifically indicated for HIV-infected adults experiencing excess abdominal fat due to lipodystrophy.

• Is Egrifta a weight loss drug?
  No, Egrifta is not for general weight loss—it is approved only for HIV-related fat buildup.

• How is Egrifta administered?
  It is given as a subcutaneous (under the skin) injection, usually once daily.

• Can Egrifta cure HIV?
  No, Egrifta does not treat or cure HIV—it only helps manage lipodystrophy.

• What are the common side effects of Egrifta?
  Injection site reactions, joint pain, muscle pain, nausea, rash, and swelling.

• Who should not use Egrifta?
  People with active cancer, pituitary gland problems, or known hypersensitivity to the drug.

• Does Egrifta interact with other medications?
  Yes, it may affect blood sugar levels and interact with insulin or other drugs—always consult your doctor.

• Can Egrifta affect blood sugar levels?
  Yes, it can increase blood sugar and may worsen diabetes in some patients.

• How soon can results be seen with Egrifta?
  Some patients may notice changes within 3–6 months of use.

• Is Egrifta safe for long-term use?
  It is intended for ongoing use under medical supervision, but regular monitoring is required.

• Can pregnant women take Egrifta?
  No, Egrifta is not recommended during pregnancy due to potential risks.

• Can Egrifta be used in children?
  No, it is not approved for use in pediatric patients.

• What happens if I miss a dose of Egrifta?
  Inject the next dose as soon as possible unless it’s almost time for the next one. Do not double dose.

• Does Egrifta cause weight loss in all body areas?
  No, it primarily reduces excess fat in the abdominal region (visceral fat).

• Can Egrifta improve cholesterol or triglyceride levels?
  In some cases, reductions in visceral fat may improve lipid levels, but it is not approved for this purpose.

• How should Egrifta be stored?
  Keep refrigerated, protected from light. Reconstituted solution should be used immediately.

• Does Egrifta have a generic version?
  As of now, no generic version is available.

• Do I need regular checkups while on Egrifta?
  Yes, doctors monitor blood sugar, IGF-1 levels, and overall health during treatment.